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Background/aim: The aim of this study was to determine the effects of resveratrol on the alterations of cavernosal eNOS and LOX-1
mRNA expression in the hypercholesterolemic condition.
Materials and methods: Twenty-one New Zealand white male rabbits were separated into three groups. Rabbits were fed with a normal
dietary intake for the control group and a 2% cholesterol diet for the hypercholesterolemia and resveratrol groups for 6 weeks. Resveratrol
4 mg/kg daily was administered for the resveratrol group. Cavernosal LOX-1 and eNOS mRNA expressions were determined with realtime RT-PCR in all groups. The statistical analysis was performed with the Kruskal–Wallis and Mann–Whitney U tests.
Results: We found no difference between mean LOX-1 mRNA expression levels in the three groups. Lower mean eNOS mRNA
expression level was determined in the hypercholesterolemia group when compared with the control group (P = 0.011). Mean eNOS
mRNA expression level in the resveratrol group was similar to that in the control group but significantly higher than that in the
hypercholesterolemia group (P < 0.001).
Conclusion: This preliminary study demonstrates the beneficial effects of resveratrol on cavernosal eNOS expression. The presence of
cavernosal LOX-1 expression was also shown for the first time. Resveratrol may be an alternative option in hypercholesterolemic erectile
dysfunction with further studies supporting its beneficial effects on the corpus cavernosum.
Key words: Hypercholesterolemia, erectile dysfunction, resveratrol, eNOS, LOX-1

1. Introduction
Erectile dysfunction (ED) and atherosclerosis share
common risk factors such as obesity, diabetes mellitus,
hypercholesterolemia, sedentary lifestyle, and metabolic
syndrome (1). Hypercholesterolemia both impairs
endothelium-dependent cavernosal smooth muscle
relaxation and inhibits vascular smooth muscle relaxation
(2–4). However, the underlying molecular mechanisms are
still unclear. Oxidized low-density lipoprotein (ox-LDL)
has many harmful effects on NO bioactivity in endothelial
dysfunction in the early stages of atherosclerosis, whereas
controversial data exist for its effects on corpus cavernosum
(5–7). Lectin-like oxidized LDL receptor-1 (LOX-1) is
the main receptor type for the proatherogenic effects of
ox-LDL and responsible for the binding, internalization,
and degradation of ox-LDL in endothelial cells (8). LOX1 expression is upregulated in atherosclerosis of large
arteries and in pathologic conditions such as hypertension,
diabetes mellitus, and hyperlipidemia (9). Its expression in
the corpus cavernosum has not been demonstrated before.
* Correspondence: drozanbozkurt@gmail.com

The most accepted pathophysiologic mechanism for
both atherosclerosis and ED is endothelial dysfunction (10).
Nitric oxide (NO) is the key molecule for the regulation
of endothelial function in the vascular walls as well as
for the induction and maintenance of erections (11). The
decreased bioactivity of NO in the penis regardless of the
reason causes vasculogenic ED (5). Endothelial nitric oxide
synthase (eNOS) is the main molecule responsible for NO
production in vascular and cavernosal structures, so it is
not surprising that decreased cavernosal eNOS expression
causes diminished NO bioactivity and subsequently ED.
Resveratrol is a polyphenol that has various rehabilitative
biochemical and physiologic effects on endothelial
functions and is found in large amounts in Polygonum
cuspidatum, grape skin, and red wine. Resveratrol
augments NO bioavailability by some mechanisms, one
of which is the increased expression of endothelial nitric
oxide synthase (eNOS) in myocardium and vascular
endothelial cells (12–14). Resveratrol significantly
improved erectile functions and demonstrated relaxant
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effects on cavernosal tissues in hypercholesterolemic and
diabetic animal models (15–17). This preliminary study
explores the effects of resveratrol on cavernosal eNOS and
LOX-1 expression in hypercholesterolemic rabbits.
2. Materials and methods
2.1. Experimental animals and hypercholesterolemia
conditioning
The study protocol was approved by the institutional review
board (Protocol No. 99/2007). Twenty-one 3-month-old
New Zealand white male rabbits weighing 2600–3200
g were obtained from the Department of Experimental
Animals in our university. They were randomly divided
into three groups with 7 rabbits in each group: control,
hypercholesterolemia (HC), and resveratrol groups.
Rabbits were housed individually in different cages in an
air-conditioned room under a 12-h light/dark cycle. All
rabbits were fed with a standard laboratory diet for at least
7 days before the initiation of the study. The rabbits in the
control group were fed with a regular diet and drinking
water for 6 weeks. The rabbits in the hypercholesterolemia
and resveratrol groups were fed with a 2% (w/w)
hypercholesterolemic diet and drinking water for 6 weeks.
Resveratrol (Sigma Aldrich) at a daily dosage of 4 mg/kg
was also administered via drinking water for the resveratrol
group (15,18). All rabbits were weighed at the beginning
and the end of the study. After 6 weeks, the rabbits were
sacrificed with high-dose thiopental. Blood samples were
obtained for the measurement of plasma total, LDL, and
HDL cholesterol levels (Roche Diagnostic, Tokyo, Japan).
The penis was excised and the corpus cavernosum was
dissected free from surrounding structures such as the
tunica albuginea and corpus spongiosum.
2.2. Real time reverse transcription-polymerase chain
reaction (RT-PCR)
TRIzol reagent (RNA-tidy-G, AppliChem) was used for
total RNA isolation. One milliliter of TRIzol solution was
added for 100 mg of tissue sample. The suspension was
treated with DNAse, and after a waiting period of 15 min at
room temperature, the suspension was homogenized with
an autohomogenizator (Heidolph Silent Crusher S). After

centrifugation RNA was separated from DNA and protein
with 0.2 mL of chloroform (AppliChem). Isopropanol
(0.5 mL; AppliChem) was used for the precipitation
of RNA. The RNA pellet was washed with 1 mL of 75%
ethanol (Merck) twice and the ethanol was removed.
After 60 min of air-drying, 50 µL of RNase-free water
(QIAGEN) was used for the solubilization of the RNA
pellet and total RNA was isolated. The amount of RNA
was determined by measuring the absorbance at 260 nm
on a spectrophotometer (OPTIMA SP-3000 PLUS). Then
1 µg of total RNA was reverse-transcribed into cDNA with
the Roche Transcriptor First Strand cDNA Synthesis Kit
according to the manufacturer’s protocol. The obtained
cDNA was preserved at –20 °C until RT-PCR application.
Quantitative RT-PCR was performed with the Roche Light
Cycler 1.5 using 2 µL of cDNA for each sample. Proper
temperature adjustments were set for denaturation,
cooling, elongation, and melting phases. Amplification
was carried out with the FastStart DNA Master HybProbe
(Roche) by specific mRNA primer pairs and hybridization
probes (TIB MOLBIOL) for GAPDH (glyceraldehyde-3phosphate dehydrogenase), eNOS, and LOX-1 (Table 1).
Amplified products were visualized on 1.5% agarose gels
with the use of ethidium bromide.
Standard curves were made up with the dilution method
using Light Cycler 3.0 software and absolute mRNA
expression levels for the internal control GAPDH and the
target genes LOX-1 and eNOS were determined with the
comparative threshold cycle (Ct) method. GAPDH was
used as an internal control for RT-PCR analysis because
it is one of the most universally used internal controls and
its expression is consistent at different time points and
various experimental manipulations (19). The relative
amount of the expression levels of target genes’ LOX-1
and eNOS mRNA to the housekeeping GAPDH mRNA
expression levels were calculated for the three groups and
mean expression levels were compared.
2.3. Statistical analysis
All data were expressed as mean ± standard error. Statistical
analysis was performed with the Kruskal–Wallis test for
the comparisons between all experimental groups and the

Table 1. Rabbit GAPDH, LOX-1, and eNOS specific primer sequences.

GAPDH

FW

RW

5’- TgTgAAgCTCATTTCCTggTATg

5’- gTTTCATgACAAggTAgggCTC

LOX-1

5’- gAATATACTggAgggACAggTCTTAg

5’- CTggAATgggAAgTCgCT

eNOS

5’- CTggAggATgTggCCgT

5’- CTCTggCCTTCTgCTCATTCT

FW: Forward primer, RW: reverse primer, GAPDH: glyceraldehyde-3-phosphate dehydrogenase, LOX1: lectin-like oxidized LDL receptor-1, eNOS: endothelial nitric oxide synthase.
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Mann–Whitney U test for two groups at a significance
level of P < 0.05 with SPSS 11.0 (SPSS Inc., Chicago, IL,
USA).
3. Results
3.1. Body weight and plasma cholesterol levels
There was not any difference (P > 0.05) in mean body weight
of the rabbits between the control, hypercholesterolemia,
and resveratrol groups both at baseline and at the end of
the trial (Table 2). Plasma total, LDL, and HDL cholesterol
levels were significantly higher in the hypercholesterolemia
and resveratrol groups compared with the control group
(P < 0.001). Lower total and LDL cholesterol levels were
observed in the resveratrol group when compared with the
hypercholesterolemia group (P < 0.01). HDL cholesterol
levels did not differ significantly between these two groups
(P > 0.05, Table 3).
3.2. LOX-1 expression
LOX-1 and GAPDH expressions for the three groups are
shown by ethidium bromide staining in Figure 1. Mean
expression levels of the amount of the target LOX-1
mRNA relative to the housekeeping GAPDH mRNA in
the control, hypercholesterolemia, and resveratrol groups
were 0.67 ± 0.32, 0.39 ± 0.22, and 0.28 ± 0.13, respectively
(Figure 1) (P > 0.05).
3.3. eNOS expression
Mean expression levels of the amount of the target eNOS
mRNA relative to the housekeeping GAPDH mRNA in
the control, hypercholesterolemia, and resveratrol groups
were 4.81 ± 2.46, 0.28 ± 0.22, and 5.21 ± 1.10, respectively
(Figure 2). Statistical analysis showed that mean cavernosal
eNOS mRNA expression level for the resveratrol group was
similar to that of the control group (P > 0.05), which was
significantly higher than that of the hypercholesterolemia
group (P < 0.001).
4. Discussion
Risk factors for the development of ED show close
similarity with vascular risk factors for the development
of atherosclerosis. The most accepted pathophysiologic
mechanism for both conditions is endothelial dysfunction
(10). The fact that hypercholesterolemia impairs vascular
and cavernosal endothelium-dependent smooth muscle
relaxation and may cause vasculogenic ED has been
demonstrated in previous isometric tension studies
(2–4). In this study, the hypercholesterolemic rabbit
model formed by a 2% (w/w) high-cholesterol diet
reached approximately 72-fold higher total and LDL
cholesterol levels when compared with the control group
at the end of the sixth week, which was high enough
for the development of impaired cavernosal functions
according to these studies. In a study conducted by Seo
et al. in rabbits fed with a 2% cholesterol diet for 4 or 8

Table 2. Mean body weights of the rabbits in the three groups
at baseline and the end of the trial. Mean body weights did not
differ significantly in the three groups (P > 0.05).
Body weight (g)
Baseline

Study end

Control (n = 7)

2752.8 ± 59.0

2862.8 ± 78.5

Hypercholesterolemia (n = 7)

2708.6 ± 65.3

2878.6 ± 86.2

Resveratrol (n = 7)

2861.4 ± 57.3

2993.6 ± 75.4

weeks, acetylcholine-induced relaxation (endotheliumdependent) of the corpus cavernosum was significantly
reduced in the hypercholesterolemia group compared to
the control group, whereas no difference was observed with
direct smooth muscle relaxant papaverine (endotheliumindependent) between the experimental and control
groups (20). They also determined decreased eNOS activity
in the hypercholesterolemia group and concluded that
impaired cavernosal relaxation in hypercholesterolemia
may be related to the functional impairment of eNOS.
The hypercholesterolemic rabbits in the present study
also had a lower eNOS expression level compared to the
control group, which is postulated as one of the reasons for
decreased eNOS activity. We also demonstrated impaired
cavernosal functions with the same experimental method
in our previous study; this is why we did not perform
functional studies again in the present study (15).
There is debate over the effects of ox-LDL on corpus
cavernosum smooth muscle. While some authors
suggested that ox-LDL decreased endothelium-dependent
relaxation responses, others reported that ox-LDL did
not change cavernosal relaxation responses (5–7). Direct
contractile effects of ox-LDL on cavernosal smooth muscle
have also been demonstrated (21). Ox-LDL has a significant
role in proatherogenic endothelial dysfunction. The main
receptor for the endothelial dysfunction in proatherogenic
processes with ox-LDL is LOX-1. Sawamura et al. showed
that LOX-1 is essential for the binding, internalization, and
degradation of ox-LDL in endothelial cells and it is highly
expressed in vascular-rich organs such as the placenta,
lungs, and brain as well as in atherosclerotic lesions (8).
In spite of its vascular-rich structure, the presence of
LOX-1 in the corpus cavernosum and its possible role
in hypercholesterolemia-associated impotence have not
been explored previously. To our knowledge, cavernosal
LOX-1 expression and possible alterations in the
hypercholesterolemic condition were evaluated for the
first time in the present study. We found no significant
difference between mean cavernosal LOX-1 expression
level in the control, hypercholesterolemia, and resveratrol

1085

BOZKURT et al. / Turk J Med Sci
Table 3. Average plasma cholesterol levels at the end of the sixth week. Total and LDL cholesterol levels were
significantly lower in the resveratrol-treated group compared to those in the hypercholesterolemia group.
Control (n = 7)

Hypercholesterolemia (n = 7)

Resveratrol (n = 7)

Total cholesterol (mg/dL)

35.0 ± 5.7

2508.0 ± 252.0

1357.8 ± 342.4 a,b

LDL (mg/dL)

6.4 ± 1.3

859.1 ± 73.0 a

495.6 ± 107.0 a,b

HDL (mg/dL)

6.4 ± 0.9

27.1 ± 1.7

23.7 ± 3.8 a

a

a

Control group vs. hypercholesterolemia and resveratrol groups; P < 0.001.
Resveratrol group vs. hypercholesterolemia group; P < 0.01.

a

b

Figure 1. Cavernosal mean LOX-1 mRNA expression level in the three groups and the demonstration
of cavernosal LOX-1 expression with ethidium bromide staining using one representative sample
from each group. Quantitative analysis showed no significant difference between groups (P > 0.05).
HC: Hypercholesterolemia.

Figure 2. Cavernosal mean eNOS mRNA expression level in the three groups and visualization of PCR products on agarose gel with
ethidium bromide staining with one representative sample from each group. Lower eNOS signal intensity in the sample from the
hypercholesterolemia group is observed in comparison to the control and resveratrol groups. HC: Hypercholesterolemia, a; P < 0.001
for HC vs. control and HC vs. resveratrol groups.
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groups in this preliminary study. It is known that LOX1 expression is upregulated in the atherosclerosis of large
arteries in pathologic conditions such as hypertension,
diabetes mellitus, and hyperlipidemia, all of which are
also important risk factors for vasculogenic erectile
dysfunction (9). One might thus expect the impairment of
cavernosal LOX-1 expression in the hypercholesterolemic
condition. Considering the results of the present study,
it may be hypothesized that cavernosal structures are
composed of small vessels and LOX-1 may not have a
pioneering role in small vessels as it has in large arteries.
Nevertheless, in order to clarify whether LOX-1 has
any role in hypercholesterolemia-induced ED or not,
further trials are mandatory before making any clear-cut
recommendations.
Resveratrol was proposed as a promising agent in
cardioprotection in a recent report by Penumathsa et
al. with its various biochemical and physiologic effects
(22). The most prominent effect of resveratrol seems
to come from the upregulation of NO bioavailability
in pathologic conditions such as ischemia/reperfusion
injury, hypercholesterolemia, or diabetes. Wallerath et
al. studied the effects of resveratrol on eNOS activity
and expression in human umbilical vein endothelial cell
cultures. They found that resveratrol upregulated eNOS
mRNA expression, eNOS protein expression, eNOS
activity, and eNOS promoter activity (23). In a previous
study conducted by our group, we evaluated the effects
of resveratrol on different vascular structures such as the
thoracal aorta, mesenteric artery, renal artery, and corpus
cavernosum by isolated tissue bath experiments in the
hypercholesterolemic status. We demonstrated that a 2%

high cholesterol diet for 6 weeks significantly impaired
cavernosal relaxation responses. Endothelium-dependent
relaxation responses induced by acetylcholine were
significantly higher in the control and resveratrol groups
when compared with the hypercholesterolemia group in
that study (15). In this preliminary study, we evaluated
cavernosal eNOS expression in three groups with the same
experimental model and determined that mean eNOS
expression levels in the resveratrol and control groups were
significantly higher than that in the hypercholesterolemia
group. With these findings we propose that protected
cavernosal eNOS expression by resveratrol may be one
of the precluding effects of resveratrol on the corpus
cavernosum in the hypercholesterolemic condition. One
limitation of the present study is that we solely evaluated
eNOS mRNA expression, not the protein expression or
eNOS phosphorylation, which are also important aspects
of NO bioactivity.
In conclusion, we demonstrated for the first time that
resveratrol has beneficial effects on cavernosal eNOS
expression in the hypercholesterolemic condition. This
might be considered as one of the mechanisms for the
restorative effects of resveratrol on cavernosal structures in
vasculogenic impotence. The presence of cavernosal LOX1 expression was also shown for the first time. However,
more extensive research on this topic is necessary in order
to better identify and support these findings.
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